Osman HA, et al. - Given the correlation of hepatitis C virus (HCV)–HBV coinfection with the rapid progression of liver disease without precise diagnosis and treatment, researchers examined if HBV antiviral therapy have any role in treating patients with HBV reactivation after direct-acting antiviral therapy in HCV–HBV coinfected patients. In this prospective random study on 140 patients who had pretreatment HBeAg seroconversion, HBV DNA < 2,000 IU/mL, normal liver enzymes, and F0/F1 hepatic fibrosis, treatment was provided with sofosbuvir 400 mg and daklatasvir 60 mg once daily for 3 months. In all the patients, negative HCV PCR at 1 month posttreatment and sustained virologic response with negative HCV PCR 3 months after treatment end were evident. HBV reactivation with raised HBV DNA PCR and liver enzymes developed in four patients. Observations suggest that with close monitoring, direct-acting antiviral therapy without HBV antiviral treatment could be provided to HBV–HCV coinfected patients who have no/mild hepatic fibrosis, HBeAg seroconversion, and HBV DNA < 2,000 IU/mL.